Physician profile
Michael T Lin
NPI 1679521025
$8,464.65
in general payments reported to CMS, 2019-2025
41 companies · $1,505 in 2025
The $1,505 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $1,158 · 2021: $1,505 · 2022: $1,238 · 2023: $1,302 · 2024: $1,229 · 2025: $1,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,021 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,021.22 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,480.02 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $984.05 | 2019-2025 | |
| Abbvie INC. | $830.17 | 2021-2025 | |
| Lilly USA, LLC | $816.78 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $561.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $476.50 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $375.47 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.73 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Vanda Pharmaceuticals INC. | $156.71 | 2020-2023 | Hetlioz |
| Bayer Healthcare Pharmaceuticals INC. | $139.31 | 2022-2025 | |
| Mylan Specialty L.P. | $119.97 | 2020-2022 | |
| Allergan, INC. | $111.21 | 2020 | |
| Merck Sharp & Dohme LLC | $93.16 | 2019-2023 | Verquvo, Belsomra, Steglujan |
| Takeda Pharmaceuticals U.S.A., INC. | $86.04 | 2019-2023 | Gattex |
| Otsuka America Pharmaceutical, INC. | $84.73 | 2022-2025 | Rexulti |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.